The Polish Stem Cell Bankestablished cooperation with the biotechnology company Dystrogen Therapeutics. The agreement will enable joint research on chimeric cells and PBKM’s production of ATMP stem cells based medicinal products – PBKM informed in a press release. Dystrogen Therapeutics SA was founded in 2017 by prof. Maria Siemionow and Dr. Kris Siemionow. “We are also connected with capital, because recently PBKM became a minority shareholder in Dystrogen” – said Jakub Baran, president of PBKM. Cell therapy with the use of chimeric cells (DEC) is to be used in all patients with Duchenne muscular dystrophy (DMD).
Menu
